Paradigm Genetics has appointed Douglas Morton, former vice president of Pfizer and current CEO of the Southwest Michigan Innovation Center, to its board of directors.

Morton joins Paradigm’s board as part of the company’s recently completed acquisition of TissueInformatics. RTP-based Paradigm acquired the Pittsburgh-based company for more than $4 million in an all-stock deal.

Morton has spent his entire career in the pharmaceutical industry, joining the Upjohn Company as a research scientist in 1973. He remained with the surviving entity through Upjohn’s merger with Pharmacia, the consolidation with Monsanto, and, recently, its merger with Pfizer.

At the time of the Pfizer merger, Morton was group VP of technology acquisitions & operations for discovery research. In this position, he was responsible for technology acquisition and operations for worldwide discovery research throughout Pharmacia.

Since retiring from Pfizer in 2003, Morton has served as CEO of the Southwest Michigan Innovation Center, an incubator that provides wet-lab space, access to venture funding and business services to emerging companies in biosciences and high technology. He has served on the Board of TissueInformatics from May 2003 until the closing of Paradigm’s acquisition of the company.

“With Doug, we gain exceptional perspective and leadership from a seasoned pharmaceutical executive with a highly productive and diverse career,” said Heinrich Gugger, president and CEO of Paradigm. “His appointment reflects the rapid evolution of our human health business and the board’s commitment to its success. Doug not only understands the practical challenges of finding new drugs, he also brings an important perspective on the role of new technologies in the drug discovery process–.”